Talaporfin sodium (TS) is a photosensitizer with proven selective vascular effects in preclinical studies, an acceptable photosensitivity period of 5-7 days, and good safety data (Akimoto et al, 2012; Bromley et al 2011; Kujundzic et al 2007) . Previously, we determined that the characteristic radiant exposure required for persistent vascular shutdown (RE 50/7 value) for TS-mediated PDT, using a custom-built LED array (664nm, FWHM = 20nm), was 85J/cm 2 (Moy et al, 2012) . Based on these and other published data Smith et al, 2006; Tournas et al, 2009 ), we hypothesized that dual phototherapy treatment with TS-mediated PDT and ensuing PDL therapy, will achieve persistent vascular shutdown with otherwise sub-therapeutic radiant exposures of PDT and PDL. To test this hypothesis, we performed studies to determine the RE 50/7 to achieve persistent vascular shutdown with PDL irradiation and the associated RE 50/7 values for dual phototherapy. We postulate that lower radiant exposures can be used for both TS-mediated PDT and ensuing PDL, minimizing adverse effects, allowing treatment of all skin types and potentially achieving enhanced treatment efficacy, compared to either alone.
Utilizing a UC Irvine Institutional Animal Care and Use Committee approved protocol, we installed dorsal window chambers (Moy et al, 2011) on adult C3H mice (25-30g, n=38) anesthetized with isoflurane. For PDT, we utilized a custom-built light emitting diode array centered at 664-nm excitation (FWHM=20nm). For TS-mediated PDT, we reconstituted TS (Light Sciences Oncology; Bellevue, Washington) using sterile saline to form a solution of 25 mg/mL. We injected TS (5 mg/kg) into the bloodstream via retro-orbital injection and began PDT immediately afterwards (irradiance 100 mW/cm 2 ; radiant exposure 0-260 J/cm 2 ). For PDL irradiation, we used a clinical 595-nm laser (Vbeam Perfecta, Candela Corporation, Wayland, MA; 10 mm diameter spot size, 1.5 ms pulse duration, radiant exposure 3.25-10.00 J/cm 2 ). We randomized experiment order.
To test the hypothesis that the dual therapy protocol enables persistent vascular shutdown with lower radiant exposures of either PDT or PDL irradiation, we restricted our study to radiant exposure values of PDT (20-60 J/cm 2 ) and PDL (4-6 J/cm 2 ) that were below the associated RE 50/7 values for either treatment alone. We performed PDL irradiation within 5 s after PDT.
To monitor blood-flow dynamics, we used Laser Speckle Imaging (LSI) (Moy et al, 2011) . We used an experimental design based on dose-response analysis (Moy et al, 2012) . We performed 19 experiments to establish a dose-response curve for PDL and 19 experiments for PDT+PDL. We collected raw speckle images before and at time points during the ensuing week . Five of the authors (BC, WJM, KMK, BSL, and JJM) independently reviewed the SFI images collected on Day 7 and graded them as "0" (no persistent vascular shutdown) or "1" (persistent vascular shutdown achieved). Prism (version 5.0d, GraphPad Software, San Diego, CA) was used to estimate the RE 50/7 for each study. We used a F-test to compare the log (RE 50/7 ) values determined from PDT (85J/cm 2 from Moy et al., 2012) and PDT+PDL. Our null hypothesis was that the RE 50/7 values for the two studies do not differ in a statistically significant manner.
by partial-to-full recovery of blood flow and no persistent vascular shutdown ( Figure 1B) ; and 3) marked acute or delayed reduction in blood flow, followed by complete vascular shutdown at Day 7 ( Figure 1C ). With application of dose-response methodology, we estimated a RE 50/7 of 7.1J/cm 2 required to induce persistent vascular shutdown with PDL irradiation ( Figure 1D ). With PDT+PDL, the characteristic PDT radiant exposure required to achieve persistent vascular shutdown, decreased from 85 to 45J/cm 2 ( Figure 1E ). This difference in PDT RE 50/7 was found to be statistically significant (p=0.0002).
We evaluated the degree of synergy between PDT and PDL vascular effects with dual phototherapy (Madsen et al., 2002) : (1) where f PDT and f PDL are the fractions of single phototherapy experiments and f PDT+PDL is the fraction of combined experiments, which do not induce persistent vascular shutdown. An additive (or absence of any) effect is indicated by α=1, α>1 indicates a synergistic effect, and α<1 indicates an antagonistic effect. Our data (Table 1) suggest the synergistic nature (α=2.7) of PDT+PDL. Collectively, our results reveal that PDT+PDL reduces the PDT light dose required to achieve persistent vascular shutdown, even at low PDL radiant exposures. We hypothesize that TS-mediated PDT enhances persistent vascular shutdown achieved with ensuing PDL therapy, primarily via endothelial cell damage (Mitra and Foster 2008) ; mechanistic studies currently are underway.
Dual phototherapy represents a potential new approach for more effective treatment of PWS birthmarks. We have initiated an Investigational Review Board approved trial to evaluate intravenously administered TS/664 nm laser light mediated dual phototherapy for PWS treatment. Treatment has been painless and notable lesion lightening has been achieved with both PDT and PDT+PDL in a single session. Patients are photosensitive for 5-7 days postprocedure and for the first 72 hours must remain indoors with lights dimmed. Completion of this study will determine if lesion lightening is greater with dual phototherapy than PDL alone. It is our intent that this combined low energy dual phototherapy will offer clinicians and patients of all skin types improved lesion lightening in fewer treatments. We first determined the characteristic radiant exposures associated with persistent vascular shutdown following 595-nm pulsed dye laser (PDL) irradiation. We performed PDL on the epidermal side of window chambers and imaged blood-flow using Laser Speckle Imaging (LSI). We assessed persistent vascular shutdown on Day 7. We assigned a "0" score if some evidence of blood flow was present, and a "1" score if flow was no longer evident. We used dose-response analysis to calculate a characteristic radiant exposure (RE 50/7 ) at which 50% of irradiated window chambers are expected to have vascular shutdown on Day 7. (A-C) Representative LSI data associated with 595-nm PDL irradiation, in which persistent vascular shutdown was not (A,B) and was (C) achieved, using radiant exposures of (A) 4, (B) 6, and (C) 10 J/cm 2 , respectively. (D) Based on data from 19 experiments, we identified a RE 50/7 of 7.1 J/cm 2 for PDL irradiation. We then studied the combination of TS-mediated PDT and PDL irradiation. In this set of experiments, we used PDT (20 to 60 J/cm 2 ) and PDL radiant exposures (4 to 6 J/cm 2 ) that were below the RE 50/7 values of 85 J/cm 2 (Moy et al., 2012) and 7.1 J/cm 2 ( Figure 1D ), respectfully. (E) Representative maps of blood flow that demonstrate persistent vascular shutdown at Day 7. In this specific example, we applied PDT (60 J/cm 2 ) followed by PDL (6 J/cm 2 ). This combination resulted in marked acute vascular shutdown, which persisted through Day 7. (F) Based on data from 30 experiments, we determined that the characteristic radiant exposure required to achieve persistent vascular shutdown, decreased from 85 J/cm 2 with PDT alone to 45 J/cm 2 for the combined PDT +PDL protocol. Scale bars = 2mm.
